13F Holdings
中文EN

SRRK Scholar Rock Holding Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1727196 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-17.0%
TTM EPS YoY-2.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-71,732.3%
Net margin-72,563.2%
FCF margin-54,370.7%
EBITDA margin-71,501.6%

Returns

ROE-200.0%
ROA-96.4%
ROIC (approx.)-1,144.3%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets62.2%
Debt / equity1.16x
Current ratio5.41x
Interest coverage-29.23x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-24.2%
Payout ratio—
Capex / revenue35.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0——$33.19M$18.82M
R&D expense$208.44M$184.55M$121.90M$124.44M$108.47M
SG&A expense$176.21M$67.50M$49.40M$43.12M$40.27M
Operating income-$384.64M-$252.05M-$171.29M-$134.37M-$129.92M
Interest expense$6.89M$6.84M$6.50M$4.70M$2.10M
Pretax income-$377.73M-$246.29M———
Net income-$377.94M-$246.29M-$165.79M-$134.50M-$131.80M
EBITDA-$382.99M-$250.12M-$168.45M-$131.38M-$127.29M
EPS (basic)-3.29-2.47-1.99-2.26-3.59
EPS (diluted)-3.29-2.47-1.99-2.26-3.59
Weighted avg. shares (diluted)114.70M99.84M83.35M59.61M36.71M
Balance sheet
Cash & equivalents$323.53M$180.28M$104.26M$105.77M$215.33M
Short-term investments$44.04M$259.40M$178.08M$212.09M$40.16M
Receivables$0————
Inventory$0————
Current assets$385.15M$451.17M$288.19M$328.02M$265.32M
PP&E, net$1.71M$2.76M$4.60M$7.38M$9.56M
Total assets$404.27M$474.92M$311.04M$358.17M$304.44M
Current liabilities$55.42M$46.94M$32.74M$36.39M$64.30M
Short-term debt——$1.33M—$1.58M
Long-term debt$99.71M$50.15M$48.68M$49.74M$48.42M
Total debt$99.71M$50.15M$50.02M$49.74M$50.00M
Total liabilities$158.78M$106.29M$85.82M$97.93M$132.37M
Shareholders' equity$245.49M$368.63M$225.22M$260.24M$172.07M
Net debt-$223.82M-$130.14M-$54.24M-$56.03M-$165.33M
Shares outstanding108.46M93.82M75.98M51.67M35.21M
Cash flow statement
Operating cash flow-$300.04M-$200.95M-$145.23M-$132.69M-$126.79M
Capital expenditure$602,000$98,000$71,000$1.06M$5.25M
Free cash flow-$300.64M-$201.05M-$145.30M-$133.76M-$132.04M
Investing cash flow$218.69M-$76.06M$41.14M-$171.70M$134.31M
Financing cash flow$228.40M$353.03M$102.57M$194.83M$44.95M
Depreciation & amortization$1.66M$1.94M$2.84M$2.99M$2.63M
Stock-based compensation$75.60M$36.63M$27.14M$27.70M$23.15M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.